Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing

Lindsay J Dick, Andrew Gray, Asha Ram, Aileen Hume, Caroline Parris, Philip J Hogg, Moira A Elliott, Steven J Ford, Gavin W Halbert

Research output: Contribution to journalArticlepeer-review


Arsenical compounds have been used therapeutically for over 2000 years finding particular relevance as antimicrobials. After being replaced by more selective and consequently less toxic antibiotics in the last century, arsenicals have recently made a resurgence as anticancer drugs (specifically arsenic trioxide and its derivatives). Arsenical parenteral formulations require post-manufacture sterility testing; however, their intrinsic antimicrobial activity must be neutralised before testing to eliminate the possibility of false (no-growth) test results.
Original languageEnglish
Pages (from-to)1664–1669
Number of pages6
JournalJournal of Pharmacy and Pharmacology
Issue number11
Early online date18 Sep 2013
Publication statusPublished - Nov 2013


  • arsenical
  • British anti-Lewisite
  • deactivation
  • sterility
  • DMP

Cite this